Advanced Solid Tumors Cancer

Oncology
8
Pipeline Programs
2
Companies
10
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 7 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Nimbus Therapeutics
1 program
1
NDI-219216Phase 1/21 trial
Active Trials
NCT06898450RecruitingEst. Dec 2031
AbbVie
AbbVieNORTH CHICAGO, IL
7 programs
7
ABBV-176Phase 11 trial
ABBV-321Phase 11 trial
ABBV-368Phase 11 trial
ABBV-399Phase 11 trial
ABBV-428Phase 11 trial
+2 more programs
Active Trials
NCT03145909Terminated19Est. Nov 2018
NCT03234712Completed62Est. Apr 2021
NCT03071757Completed139Est. Apr 2022
+6 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AbbVieOsimertinib
Nimbus TherapeuticsNDI-219216
AbbVieOsimertinib
AbbVieABBV-CLS-579
AbbVieABBV-399
AbbVieABBV-321
AbbVieABBV-176
AbbVieABBV-368
AbbVieABBV-428
AbbVieOsimertinib

Clinical Trials (10)

Total enrollment: 709 patients across 10 trials

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Start: May 2024Est. completion: Apr 20280
Phase 3Withdrawn

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

Start: Mar 2025Est. completion: Dec 2031
Phase 1/2Recruiting

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Start: Feb 2021Est. completion: Feb 202681 patients
Phase 1Active Not Recruiting
NCT04417465AbbVieABBV-CLS-579

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Start: Jun 2020Est. completion: Aug 2025101 patients
Phase 1Completed

A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors

Start: Nov 2017Est. completion: Mar 20199 patients
Phase 1Completed

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Start: Oct 2017Est. completion: Apr 202162 patients
Phase 1Completed

A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

Start: Jul 2017Est. completion: Nov 201819 patients
Phase 1Terminated

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Start: Mar 2017Est. completion: Apr 2022139 patients
Phase 1Completed

A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors

Start: Nov 2016Est. completion: Oct 201961 patients
Phase 1Completed

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Start: Jan 2014Est. completion: Aug 2026237 patients
Phase 1Active Not Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 709 patients
2 companies competing in this space